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Abstract and Key Words 
 
 
BACKGROUND  Microvolt T-wave alternans (MTWA) testing in many studies has proven to 
be a highly accurate predictor of ventricular tachyarrhythmic events (VTEs) in patients with risk 
factors for sudden cardiac death (SCD) but without a prior history of sustained VTEs (primary 
prevention patients).  In some recent studies involving primary prevention patients with 
prophylactically implanted ICDs, MTWA has not performed as well.   
 
OBJECTIVE We examined the hypothesis that MTWA is an accurate predictor of VTEs in 
primary prevention patients without implanted ICDs, but not of appropriate ICD therapy 
(AICDT) in such patients with implanted ICDs. 
 
METHODS  We identified prospective clinical trials evaluating MTWA measured using the 
spectral analytic method in primary prevention populations and analyzed studies in which (1) 
few patients had implanted ICDs and as a result none or a small fraction (≤ 15%) of the reported 
endpoint VTEs were AICDTs (Low ICD Group) or (2) many of the patients had implanted ICDs 
and the majority of the reported endpoint VTEs were AICDTs (High ICD Group).   
 
RESULTS In the Low ICD Group comprising 3,682 patients the hazard ratio associated with a 
non-negative vs negative MTWA test was 13.6 [8.5 30.4] (brackets denote 95% confidence 
interval) and the annual event rate (AER) among the MTWA negatives patients was 0.3% [0.1% 
0.5%].  In contrast, in the High ICD Group comprising 2,234 patients the hazard ratio was only 
1.6 [1.2 2.1] and the AER among the MTWA negative patients was elevated to 5.4% [4.1% 
6.7%].  In support of these findings we analyzed published data from the MADIT II and SCD-  2
HeFT trials and determined that in those trials only 32% of patients who received AICDT 
averted a SCD. 
 
CONCLUSION MTWA testing using the spectral analytic method provides an accurate means 
of predicting VTEs in primary prevention patients without implanted ICDs; in particular, the 
event rate is very low among such patients with a negative MTWA test.    In prospective trials of 
ICD therapy the number of patients receiving AICDT greatly exceeds the number of patients 
who avert SCD as a result of ICD therapy. In trials involving patients with implanted ICDs these 
excess AICDTs appear to distribute randomly between MTWA negative and non-negative 
patients obscuring the predictive accuracy of MTWA for SCD.  AICDT is an unreliable 
surrogate endpoint for SCD.  
 
KEY WORDS Arrhythmia; Sudden cardiac death; Cardiac arrest;  ICD; T-wave alternans; 
Surrogate endpoint; Ventricular tachyarrhythmic event; Primary prevention 
 
ABBREVIATIONS MTWA, microvolt T-wave alternans; VTE, ventricular tachyarrhythmic 
event; SCD, sudden cardiac death; ICD, implantable cardioverter defibrillator; AICDT, 
appropriate ICD therapy; AER,  annual event rate; CA, cardiac arrest; HR, hazard ratio.   3
Introduction 
Microvolt T-wave alternans (MTWA) testing using the analytic spectral method is a non-
invasive means of stratifying patients for the risk of sudden cardiac death (SCD).    Many studies 
conducted in patients without implanted ICDs have found MTWA to be a highly accurate risk 
stratifier and, in particular, have found that the rate of ventricular tachyarrhythmic events (VTEs) 
among patients who test MTWA negative is exceedingly low
1-7 suggesting that ICD therapy may 
not benefit such patients
8.  As a result, MTWA has been proposed as a means of guiding 
implantable cardioverter defibrillator (ICD) therapy in patients with risk factors for SCD but 
without a prior history of sustained VTEs (primary prevention patients). 
With the advent of the MADIT II
9 and SCD-HeFT
10 trials, clinical guidelines have 
recommended prophylactic ICD implantation in patients with left ventricular dysfunction and no 
prior history of VTEs.   As a result, a number of recent clinical trials conducted to evaluate 
MTWA testing have involved patients with prophylactically implanted ICDs
11-15.  Such trials 
have generally utilized appropriate ICD therapy (AICDT) as the predominant component of the 
VTE endpoint.  AICDT is defined as an ICD therapy deemed to be appropriate based upon 
expert review of the stored electrogram recorded immediately prior to the delivery of ICD 
therapy.  MTWA testing has tended to not perform as well in these latter trials involving patients 
with implanted ICDs.   
  It had been assumed that, in patients with implanted ICDs, AICDT would be a reliable 
surrogate for sudden cardiac death.  Recent analyses of ICD trials
16, 17 have concluded that 
AICDTs in the ICD arms of the studies exceeded sudden deaths in the control arms by a factor of 
two to three. These analyses raise questions about the suitability of AICDT as a surrogate 
endpoint for SCD in clinical trials
18.   4
  In this paper we analyze clinical trials conducted to evaluate MTWA as a predictor of 
VTEs in primary prevention patients.  We compare trials in which few patients had implanted 
ICDs (and therefore in which VTE endpoint events included none or few occurrences of AICDT) 
with trials in which many patients had implanted ICDs and thus AICDTs comprised the majority 
of the VTE endpoints.  We also analyze data from the MADIT II
9 and SCD-HeFT
10 trials to 
determine what fraction of the reported AICDTs in those studies terminated VTEs that would 
have been lethal had no ICD been implanted in order to elucidate the findings from the analyses 
of the MTWA studies.   
 
Methods 
Identification of Clinical Trials 
On November 17, 2007 we conducted a PubMed online search for journal publications which 
included the word alternans in the title and were published after 1993.  From this list we 
identified prospective clinical trials in which MTWA was measured using the spectral analytic 
method, involved at least 100 patients with a significant risk factor for sudden cardiac death but 
not selected on the basis of a known history of sustained VTEs, and had a mean follow-up period 
of at least 12 months.  We excluded studies which included patients who underwent MTWA 
testing earlier than 14 days after a recent myocardial infarction (MI).  One study
19 was excluded 
because it reported on a subset of patients reported in a later publication.  We also included in 
our analysis data from recent major studies presented at national meetings (ABCD
14, SCD-HeFT 
substudy
15, and MASTER I
13) which had not yet been published in journal articles.  We defined 
the Low ICD Group to include trials identified above which reported VTE endpoints in which 
AICDT events accounted for none or a small fraction (≤ 15%) of the reported VTE endpoints –   5
few patients in these studies had implanted ICDs.  We defined the High ICD Group to include 
trials identified above which reported VTE endpoints in which AICDTs constituted the majority 
of the reported VTE endpoint events. 
 
Statistical Analysis 
In order to compare endpoint data across studies with different follow-up periods, event data 
were converted to annual event rates (AERs).  The annual event rate, λ, was computed from the 
equation S = e
-λ T where S is the survival value at time T.  S and T were determined either (i) from 
the published survival curves (resulting from Kaplan Meier or Cox analyses) by measuring S at 
the maximum displayed survival time, T or (ii) from published data which reported the fraction, 
F,  of patients in each subgroup who had sustained endpoint events during follow-up and setting 
S = 1 - F and T to the mean reported follow-up period.  The hazard ratio (HR) for two subgroups 
was obtained by computing the ratio of the derived AERs.  
  For each subgroup in each study we assumed that the occurrence of endpoint events 
follow time-dependent binomial statistics and used Bayes theorem to obtain the posterior 
probability distribution for S conditional on n,  p(S/n), where n = (1 – Sexp)N,  Sexp  is the 
experimentally measured value of S, and N is the initial total number of subjects: 
n N nS S n N C N n S p
− − + = ) 1 )( , ( ) 1 ( ) / (.  
Here C(N,n) denotes a binomial coefficient.  The mean and standard deviation of each AER were 
obtained from the analytically calculated moments of ln(S).   Weighting factors proportional to 
the reciprocal of the variances of corresponding AERs in different studies were used to obtain 
the minimum variance estimate of the cumulative AER.  Confidence intervals of the cumulative 
AERs and their ratios were computed numerically assuming that the cumulative AER estimates   6
were Normally distributed.  Differences in cumulative AERs were considered statistically 
significant based on a two-sided p < 0.05. 
  Cumulative left ventricular ejection fractions (LVEFs) were calculated by weighting 
reported LVEFs by the number of patients in each study.   
 
Results 
Predictive Accuracy of MTWA Testing 
Tables 1 and 2 display data from prospective trials conducted to evaluate the predictive accuracy 
of MTWA testing measured using the spectral analytic method in patients with a significant risk 
factor for SCD but not selected on the basis of a known prior history of sustained VTEs.  The 
trials presented in these tables all reported ventricular tachyarrhythmic event (VTE) endpoints.  
Table 1 displays data from the Low ICD Group of MTWA  trials in which few patients had 
implanted ICDs and ≤ 15% of the reported VTEs were AICDTs.   Among the 3,682 patients 
enrolled in these studies, the cumulative AER among MTWA negative patients was 0.3% [0.1% 
0.5%] and among MTWA non-negative patients was 4.4% [3.7% 5.1%] (HR for MTWA non-
negative versus negative, 13.6 [8.5 30.4]).  Here brackets denote 95% confidence interval. In the 
subset of studies including patients with a mean LVEF < 0.30, the corresponding cumulative 
AERs were 1.2% [0.5% 2.0%] and 6.3% [4.5% 8.0%] (HR, 5.2 [2.9 13.8]).  In subset of studies 
which included only SCD and cardiac arrest (CA) - but not non-fatal sustained ventricular 
tachyarrhythmia - as an endpoint, the cumulative AERs were 0.3% [0.1% 0.5%] among the 
MTWA negative patients and 4.1% [3.1% 5.1%] among the MTWA non-negative patients (HR, 
15.3 [8.5 46.1]).  In the Low ICD Group and each of the presented subsets, the MTWA negative   7
versus non-negative cumulative AERs are significantly different (p < 0.0001) and the HRs all 
significantly exceed one. 
  In contrast, in Table 2 we present the AERs from the High ICD Group of MTWA trials in 
which many patients had implanted ICDs and AICDT comprised the majority of the endpoint 
events.  Among the 2,234 patients in these trials, the AERs were 5.4% [4.1% 6.7%] among the 
MTWA negative patients and 8.5% [7.5% 9.6%] among the MTWA non-negative patients (HR, 
1.6 [1.2 2.1]).  While in the High ICD Group the hazard ratio narrows substantially compared to 
the hazard ratio in the Low ICD Group (and each of the presented subsets), the hazard ratio 
remains significantly greater than unity.  The MTWA negative and non-negative cumulative 
AERs in the High ICD Group are each significantly greater than the corresponding values for the 
Low ICD Group (and each of the presented subsets).   
  Figure 1 illustrates the values of the cumulative AERs in MTWA negative and non-
negative patients, as well as the associated hazard ratio, in the Low and High ICD Groups.  
  In Table 3 we calculate from analysis of published data the ratio of the annual rate of 
AICDT to the annual rate of ICD mediated reduction in mortality in the MADIT II and SCD-
HeFT trials.  This ratio is 3.1 [2.0 6.3].  The ratio implies that only 1 in 3.1 patients (32%) who 
received AICDT in MADIT II and SCD-HeFT averted a sudden death that would have occurred 
in the absence of ICD implantation. 
  In Table 4 we present mortality rates in the MADIT II and SCD-HeFT trials and in 
MTWA trials involving predominantly patients without implanted ICDS in which the mean 
LVEF < 0.30 and which reported total mortality endpoint data.  In the non-ICD arm of the 
MADIT II and SCD-HeFt trials, the annual mortality rate was 9.5%.  In the entire population of 
the MTWA trials presented here, the annual mortality rate was 5.4%.  In the ICD arm of the   8
MADIT II and SCD-HeFT trials, the annual mortality rate was 7.3%.  In the MTWA negative 
patients in the corresponding MTWA trials the annual mortality rate was only 1.7%.  The annual 
mortality rate among MTWA negative patients who predominantly did not receive ICDs was 
significantly lower, by a factor of 4.3, than among patients in MADIT II and SCD-HeFT who did 
receive ICD therapy. 
 
Discussion 
Predictive Accuracy of MTWA 
The above analysis of MTWA trials demonstrates that there is a substantial and 
consistent difference in the reported VTE predictive accuracy of MTWA testing performed using 
the spectral analytic method in trials in which the endpoint involved a low or high fraction of 
AICDTs.  In the Low ICD Group, involving patients primarily without implanted ICDs,  the 
hazard ratio was 13.6 for annual VTE rates in MTWA non-negative compared to MTWA 
negative patients (hazard ratio was 5.2 in studies in which the mean LVEF < 0.30).  The hazard 
ratio increases to 15.3 when only SCD and CA, but not non-lethal sustained VTEs, are included 
in the endpoint.  In contrast, in patients in the High ICD Group, the hazard ratio falls to 1.6.  
Similarly, the annual VTE rate in the Low ICD Group is only 0.3% (1.2% in studies in which 
mean LVEF < 0.30);  the annual VTE is 0.3% when only SCD and CA are included in the 
endpoint.  In contrast, the annual VTE rate among MTWA negative patients is 5.4% in the High 
ICD Group  – greater by an order of magnitude. 
In our analysis we also demonstrate that in MADIT II
9 and SCD-HeFT
10 only 1 in 3.1 
patients (32%) who received AICDT averted a SCD that would have occurred in the absence of 
ICD implantation.  This result is consistent with the reports of other investigators who have also   9
found that the number of AICDTs greatly exceeds the ICD mediated reduction in deaths in 
clinical ICD trials
16, 17.  One explanation for the excess number of AICDTs is that ICDs treat 
arrhythmias that would have self-terminated had no ICD been implanted.  Another possible 
explanation is that ICDs are themselves arrhythmogenic and induce arrhythmias that they then 
end up treating
17.  Whatever the mechanism, the large excess of the number of patients receiving 
AICDT over the number of patients averting SCD indicates that AICDT is an unreliable 
surrogate for a SCD endpoint in clinical trials
18.  The large number of patients studied in clinical 
trials involving predominantly non-ICD patients have shown that MTWA as measured by the 
spectral analytic method is a highly accurate predictor of spontaneous VTEs, in particular SCD 
and CA.  In contrast, it appears that MTWA does not predict the excess AICDTs.  When AICDT 
is used as an endpoint in a clinical trial, these excess AICDTs appear to play the role of statistical 
noise being randomly distributed as endpoint events among the MTWA negative and non-
negative subgroups. 
It should be mentioned that there is variation in the thresholds set for triggering AICDT 
across different trials (and even within trials) which may lead one to speculate that AICDTs 
triggered at higher set thresholds might constitute more suitable surrogate endpoints for SCD.  
Daubert
20 found that in MADIT II
9 that ICD therapy for fast VT/VF with rates > 240 bpm 
occurred at the same frequency in ICD patients as excess mortality occurred in patients without 
ICDs.  A rate > 240 bpm far exceeds what has been deemed clinically acceptable in terms of a 
threshold for triggering AICDT therapy.  However, occurrence of VT/VF with a heart rate > 240 
bpm might be a candidate surrogate endpoint for SCD in patients with ICDs even if the threshold 
is set at a lower rate.  Such an endpoint would be a reliable surrogate for SCD only if rate is the 
primary factor in determining the lethality of a tachyarrhythmia.  Also, if the mechanism for the   10
excess AICDTs is an arrhythmogenic effect of the ICD itself as discussed above, such an 
endpoint would still result in excess AICDTs and remain a poor surrogate for SCD. 
MTWA in Non-Ischemic Dilated Cardiomyopathy Patients 
  In Table 1 three studies present data exclusively on patients with non-ischemic dilated 
cardiomyopathy.  The results of Kitamura
3 (104 patients) and ALPHA
7 (446 patients), with 
hazard ratios of 10.0 and 5.1, are well within the range of results obtained in patients with 
ischemic heart disease.  Also, Bloomfield
5 (549 patients), using a mixed endpoint of non-fatal 
sustained ventricular arrhythmias and all cause mortality, reported no difference in the predictive 
accuracy of MTWA in ischemic and non-ischemic patients.    However, Table 1 reports a hazard 
ratio of only 1.9 for the Grimm
21 (263 patients) study of non-ischemic dilated cardiomyopathy 
patients.  This study, while it is included in the summary statistics, appears to be an outlier.  One 
possible explanation for MTWA performance in Grimm
21 compared to the other studies of 
MTWA in DCM patients might be that in Grimm beta-blockers were withheld for at least 24 
hours prior to MTWA testing while 74% of patients took beta-blockers during follow-up.  In 
contrast in ALPHA
7, Kitamura
3, and Bloomfield
5 were not withheld prior to MTWA testing.   It 
is known that beta-blockers both reduce the incidence of ventricular tachyarrhythmias and – 
particularly in patients with non-ischemic cardiomyopathy - suppress MTWA
22, 23.  Thus, in 
Grimm
21 it is possible that the withdrawal of beta-blockers acutely increased the incidence of 
MTWA without concomitantly increasing VTEs during follow-up because these same patients 
were taking beta-blockers during follow-up.  The results of these studies suggest that it may be 
advisable to perform MTWA tests in patients while they are on the same pharmacologic regimen 
as they will be on during follow-up.  Only if patients have an indeterminate test because they 
cannot achieve the minimum heart rate of 105 bpm, would it be advised to withdraw beta-  11
blockers to the extent needed for the patient to achieve this heart rate.  (Of note, many patients 
who on initial exercise testing cannot achieve a heart rate of 105 bpm can do so upon repeating 
the exercise test after a short rest period.) 
 
Benefit of ICD Therapy in MTWA Non-Negative versus Negative Patients 
ICD therapy  is associated with its own morbidity and mortality including infection, lead 
breakage, inappropriate shocks, perforation, device and lead recalls
17.  The early complication 
rate associated with just the ICD implantation procedure itself has been reported to be 11% 
including a mortality rate of 1%, exclusive of the complications after hospital discharge such as 
inappropriate shocks and lead breakage
24.  The cumulative complication rate for ICDs has been 
reported as 31% over 46 months of follow-up
25.  Potentially at-risk primary prevention patients 
with a negative MTWA test have only a 0.3% annual risk of SCD and CA (Table 1) suggesting 
that the risk of ICD therapy may outweigh the benefit in these patients.   No clinical trial has ever 
demonstrated that ICD therapy provides a mortality benefit in patients with an annual risk of 
SCD or CA even remotely as low as one percent or less.  Thus there is no clinical evidence that 
patients without a prior history of sustained ventricular arrhythmias and a negative MTWA test 
benefit from ICD therapy.  The DINAMIT
26 study demonstrated that ICD therapy was associated 
with a significant increase in non-arrhythmic mortality of 2.6% per year (p = 0.02), suggesting 
that ICD therapy may have an adverse effect on total mortality in a patient population with an 
annual arrhythmic mortality of less than 2.6%. 
Table 4 shows that, in MTWA studies involving patients with LVEF < 0.30, the annual 
total mortality rate was 57% of that observed in the non-ICD arms of the MADIT II
9 and SCD-
HeFT
10 trials.  An explanation for this observation is possible referral bias in MADIT II and   12
SCD-HeFT where physicians referring patients into these treatment trials pre-selected patients 
that they believed would be at higher risk of SCD and thus more likely to benefit from ICD 
therapy.  In the natural history MTWA trials no therapy was mandated so there would be little 
reason to expect a similar referral bias.  Of greater interest is the fact that the mortality rate 
among the MTWA negative patients presented in Table 4 who predominantly did not receive 
ICD therapy had a factor of 4.3 lower mortality rate than the patients in MADIT II and SCD-
HeFT who did receive ICD therapy.  Even if one adjusts for the overall lower mortality rate in 
the MTWA trials compared to MADIT II and SCD-HeFT, the MTWA negative patients who 
predominantly did not receive ICDs still had a 2.4 times lower mortality rate than the MADIT II 
and SCD-HeFT patients who did receive ICD therapy.  This observation further suggests that 
MTWA patients without a history of sustained VTEs may not benefit from ICD therapy. 
Chow et al, 2007
27 conducted a prospective non-randomized study of 768 patients with 
ischemic heart disease and LVEF ≤ 0.35 of whom 51% received ICDs.  In this study the 
propensity score statistical methodology was used to adjust for factors that affect the decision to 
implant an ICD.  These investigators found that ICD implantation in MTWA non-negative 
patients was associated with a 55% reduction in all-cause mortality (p < 0.003), but that ICD 
implantation in an equivalent number of MTWA negative patients had no statistically significant 
effect on mortality. 
MTWA as a Guide to ICD Therapy 
  In the US, ICD therapy is generally reimbursed by third party insurers for patients with 
symptoms of heart failure with LVEF ≤ 0.35.  The American Heart Association estimates that 
there are 5.2 million patients in the United States with symptomatic heart failure
28.  Solomon et 
al
29 studied 7,599 patients with symptomatic heart failure and found that approximately 44% had   13
LVEF ≤ 0.35.   These data suggest that in excess of two million primary prevention patients may 
qualify for reimbursable ICD therapy. However, only approximately 100,000 ICDs per year are 
being implanted in the United States in this patient population.  This suggests that there may be a 
reluctance to accept ICD therapy for this population among referring physicians and patients.  
Recent recalls of devices and leads reported prominently in the popular press may have served to 
reinforce this reluctance. 
  MTWA testing as an accurate non-invasive means of assessing risk of SCD a may serve 
to identify patients most likely to benefit from ICD therapy.  Approximately one-third of the 
symptomatic patients with LVEF ≤ 0.35 may test MTWA negative
7, 12.  However, a non-negative 
test in the remaining patients may serve as a specific call to action for the patient and referring 
physician.  As a result, a greater number of appropriate patients may receive ICD therapy.  Ikeda 
et al
6 demonstrated in patients with a prior MI and LVEF > 0.40 that a positive MTWA 
identified patients at significant risk of SCD.  This finding is supported by another recent 
publication
30 in a population with prior MI and mean LVEF of 0.47.  Thus MTWA may play a 
role in identifying patients with a significant risk factor for SCD but with only moderate left 
ventricular dysfunction who need further evaluation for possible ICD therapy.   
Stecker et al
31 found that  LVEF had been measured in only 17% of 714 cases of SCD.  
In the cases where LVEF had been measured, only thirty percent had LVEF ≤ 0.35.  One would 
presume that the lower a patient’s LVEF the more likely that patient would come to clinical 
attention and have his/her LVEF measured.  Thus, this study would suggest that patients with 
LVEF  ≤ 0.35 comprise a small minority of all SCDs – at most thirty percent but likely a 
substantially lower fraction.   Thus, since the substantial majority of SCDs appear to occur in   14
patients with LVEF > 0.35, it is critical to identify patients in this latter group who are at 
significant risk for SCD so that they can be evaluated for preventative therapy. 
Figure 2 illustrates a possible clinical algorithm for the use of MTWA in evaluating 
primary prevention patients.  Of note, patients who have risk factors such as LVEF ≤ 0.35 or 
prior MI and test MTWA negative should be considered for annual testing.  The myocardial 
substrate may evolve over time and MTWA as a non-invasive test can be used to monitor 
changes in arrhythmic susceptibility.  In patients with LVEF ≤ 0.35 a positive or indeterminate 
MTWA test indicate a high level of risk
32, whereas in patients with higher LVEF only a positive 
test appears to indicate elevated risk
6.   
 
Conclusion 
MTWA testing using the spectral analytic method identifies, among non-ICD patients with risk 
factors for SCD but with no prior history of sustained VTEs, a group of patients at very low risk 
for SCD and a group at elevated risk.  In prospective trials of ICD therapy the number of 
AICDTs greatly exceeds the number of SCDs prevented as a result of ICD implantation. In trials 
involving patients with implanted ICDs these excess AICDTs appear to distribute randomly 
between MTWA negative and non-negative patients obscuring the predictive accuracy of 
MTWA for SCD.   AICDT is an unreliable surrogate endpoint for SCD. 
  There is no evidence that ICD therapy provides a mortality benefit for primary prevention 
patients with a negative MTWA test.  In patients with ischemic heart disease and LVEF ≤ 0.35, 
there is evidence that ICD therapy provides a substantial mortality benefit for MTWA positive or 
indeterminate patients but not for MTWA negative patients
27.  MTWA testing may serve as a 
means of guiding ICD therapy to appropriate patients and overcoming the widespread reluctance   15
among patients and referring physicians to accept ICD therapy for appropriate patients.  MTWA 
testing may also provide a means for identifying which patients, with risk factors for sudden 
cardiac death but with LVEF > 0.35, should undergo further evaluation for preventative therapy.  
Because the substantial majority of SCDs occur in LVEF > 0.35 patients
31, substantial progress 
in reduction of SCD will only be possible when the high risk patients in this group are identified 
and treated prophylactically.    16
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Table 1 
Annual VTE Event Rates from MTWA Trials in Low ICD Group 
Study Patient 
Population 
 
Mean 
LVEF 
(%) 
Patient 
Number 
 
Arrhythmic 
Endpoint 
ICDs 
Reported 
Implanted 
at Baseline 
(%) 
AICDTs 
Reported as 
Percent of 
VTE 
Endpoints 
Non-Neg  
 
Neg 
AER 
(%) 
Non-Neg  
AER 
(%) 
HR 
Klingenheben 
et al, 2000
1 
CHF 
 
28 
 
107 
 
SCD, CA 
SusVT 
0 0  Pos 
 
0.00 
 
15.7 
 
∞ 
 
Ikeda et al, 
2002
2 
Prior MI 
 
50 
 
834 
 
SCD, CA 
 
0 0  Pos 
 
0.2 
 
3.6 
 
16.5 
 
Kitamura et al,  
2002
3 
DCM 
 
37 
 
104 
 
SCD, CA 
SusVT 
0 0  Pos 
 
1.6 
 
15.6 
 
10.0 
 
Grimm et al, 
2003
21 
DCM, 
LVEF ≤ 45% 
30 
 
263 
 
SCD, CA 
SusVT 
0 0  Pos + Ind 
 
2.1 
 
4.1 
 
1.9 
 
Hohnloser et al,  
2003
4 
CAD 
LVEF ≤ 30% 
25.5 
 
129 
 
SCD, CA 
 
0  0  Pos + Ind  0.0 
 
8.4 
 
∞ 
 
Bloomfield et 
al, 2006
5 
LVEF ≤ 40% 
No ICD subset 
25 
 
549 
 
SCD 
 
0  0  Pos + Ind  0.4 
 
NR 
   
Chow et al, 
2006
12  
CAD 
LVEF ≤  35% 
No ICD subset 
28.3 
 
 
376 
 
 
SCD 
 
 
0  0  Pos + Ind  2.3 
 
 
7.9 
 
 
3.5 
 
 
Ikeda et al, 
 2006
6 
Prior MI 
LVEF  > 40% 
55 
 
1003 
 
SCD, CA 
 
0 0  Pos 
 
0.2 
 
3.5 
 
23.1 
 
ALPHA, 2007
7 DCM 
LVEF ≤  40% 
29.5 
 
446 
 
SCD, CA 
SusVT 
0 15  Pos + Ind 
 
0.9 
 
4.8 
 
5.1 
 
Cumulative All 
 
40.5 3682 
 
      0.3 
[0.1 0.5] 
4.4** 
[3.7 5.1] 
13.6 
[8.5 30.4] 
Cumulative Mean  LVEF   
<  30% 
27.4 1478 
 
      1.2 
[0.5 2.0] 
6.3** 
[4.5 8.0] 
5.2 
[2.9 13.8] 
Cumulative Only  SCD,  CA 
Endpoints 
43.9 2762 
 
      0.3 
[0.1 0.5] 
4.1** 
[3.1 5.1] 
15.3 
[8.5 46.1] 
 
Data drawn from indicated studies.  The Non-Neg column indicates whether in the indicated 
study a non-negative MTWA test result was defined as a positive MTWA test result, or either a 
positive or an indeterminate MTWA test result.  Columns labeled ICDs Reported Implanted at 
Baseline (%) and AICDTs Reported as Percent of VTE Endpoints refer to patients identified in 
Population column if this represents a subset of all patients reported in study.  The Bloomfield et 
al, 2006
5 study reported a combined mortality plus non-fatal sustained VTE endpoint.  However, 
the study reported that the only arrhythmic event, in the subset of MTWA negative patients who 
did not receive ICDs either at enrollment or during follow-up, was one sudden cardiac death; we 
obtained the number of patients in this subset from the study database.  Chow et al, 2006
12 
reported separately the results for patients with and without ICDs; the results for the non-ICD   20
patients are reported here.  The Hohnloser et al, 2003
4 data are not included in the cumulative 
statistics because patients in this study were drawn from Klingenheben et al, 2000
1 and Ikeda et 
al, 2002
2.  Abbreviations:  AER, annual event rate; CA, cardiac arrest; CAD, coronary artery 
disease; CHF, congestive heart failure; DCM, non-ischemic dilated cardiomyopathy; Ind, 
indeterminate MTWA test result; HR, hazard ratio; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; Non-Neg, a non-negative MTWA test result; NR, not reported; Pos, 
positive MTWA test result; Neg, negative MTWA test result; SCD, sudden cardiac death; 
SusVT, sustained ventricular tachycardia; VF, ventricular fibrillation; [], 95% confidence 
interval; * (**), cumulative AER different from entry immediately to its left at the p < 0.001 (p < 
0.0001) significance level.   21
Table 2 
Annual VTE Event Rates from MTWA Trials in High ICD Group 
Study Patient 
Population 
Mean 
LVEF 
(%) 
Patient 
Number 
 
Arrhythmic 
Endpoint 
ICDs 
Reported 
Implanted 
at Baseline 
(%) 
AICDTs 
Reported as 
Percent of 
VTE 
Endpoints 
Non-Neg  
 
Neg 
AER 
(%) 
Non-Neg 
AER 
(%) 
HR 
ABCD, 
2006
14 
 
CAD, 
LVEF ≤0.40 
NSVT 
28 
 
 
566 
 
 
SCD, AICDT 
 
 
>50
† 85  Pos or Ind 
 
 
5.1 
 
 
9.4 
 
 
1.8 
 
 
Chow et al, 
2006
12 
 
CAD, 
LVEF ≤ 0.35 
ICD subset 
26 
 
 
317 
 
 
SCD, AICDT 
 
 
100 65  Pos or Ind 
 
 
4.6 
 
 
7.8 
 
 
1.7 
 
 
SCD-HeFT 
Substudy, 
2006
15 
CHF 
LVEF ≤ 0.35 
 
25 
 
 
490 
 
 
SCD, SusVT, 
AICDT 
 
~50
† >50
†  Pos 
 
 
4.2 
 
 
8.2 
 
 
1.9 
 
 
Cantillon et 
al, 2006
11 
LVEF ≤ 
0.35, NSVT 
or Syncope 
26 
 
 
286 
 
 
SCD, SusVT, 
AICDT 
 
61% >50
†  Pos or Ind 
 
 
10.5 
 
 
20.8 
 
 
2.0 
 
 
MASTER I, 
2007
13 
CAD 
LVEF ≤ 0.30 
24 
 
575 
 
SCD, AICDT 
 
100 96  Pos or Ind 
 
5.2 
 
6.8 
 
1.3 
 
Cumulative 
 
25.8 
 
2,234 
   
    5.4 
[4.1 6.7] 
8.5* 
[7.5 9.6] 
1.6 
[1.2 2.1] 
 
Data drawn from indicated studies. Chow et al, 2006
12 reported separately the results for patients 
with and without ICDs; the results for the ICD patients are reported here.  Columns labeled ICDs 
Reported Implanted at Baseline (%) and AICDTs Reported as Percent of VTE Endpoints refer to 
patients identified in Population column if this represents a subset of all patients reported in 
study.  † indicates values not explicitly reported, but confidently estimated from other reported 
information. Abbreviations:  AICDT, appropriate ICD therapy; NSVT, non-sustained ventricular 
tachycardia.  Other abbreviations as in Table 1.   22
Table 3 
Ratio of Annual Rate of Appropriate ICD Therapy to Annual Rate of ICD Mediated 
Reduction in Mortality 
 
Study Number 
of 
Patients 
Annual Rate 
of 
Appropriate 
ICD Therapy 
(%) 
Annual Rate 
of ICD 
Mediated 
Reduction in 
Mortality 
 
(%) 
Ratio 
MADIT II, 
2002
9, 33 
1232 15.3  4.1  3.8 
SCD-HeFT, 
2004
10 
1676 6.2  2.1  2.9 
Cumulative 2908  7.5 
[6.7 8.4] 
2.4 
[1.2 3.7] 
3.1 
[2.0 6.3] 
 
Annual Rate of Appropriate ICD Therapy represents the annual rate of increase in the number of 
patients having had AICDT.  Annual Rate of ICD Mediated Reduction in Mortality was obtained 
by computing the difference in the annual mortality event rates between the non-ICD and ICD 
arms of each study (see Table 4).  Number of patients in SCD-HeFT trial excludes amiodarone 
arm.    23
Table 4 
Annual Mortality Rates in MADIT II and SCD-HeFT Trials and in MTWA Trials 
Reporting Total Mortality in which Mean LVEF < 30% and Involving Patients 
Predominantly Without Implanted ICDs 
       Annual  Mortality  (%) 
Study Population  Number  of 
Patients 
Mean 
LVEF (%) 
No ICD 
 
ICD 
 
MADIT II, 2002
8, 9 Prior  MI, 
LVEF ≤ 0.30 
1,232 23  13.2  9.2 
SCD-HeFT, 2004
8, 10 CHF, 
LVEF ≤ 0.35 
1,676 25  9.0 6.8 
All    2,908 24.2  9.5 
[8.6 10.5] 
7.3* 
[6.5 8.1] 
           
Study Population  Number  of 
Patients 
Mean 
LVEF (%) 
Entire 
Population 
MTWA 
Negative
Hohnloser et al, 2003
4  CAD, LVEF ≤ 0.30  129  25.5  10.4 6.7 
Bloomfield et al, 2006
5  LVEF ≤ 0.40  549  25  4.5 0.6 
Chow et al, 2006
12  CAD, LVEF  ≤ 0.35, 
No ICD 
376 28.3 
 
11.2 5.8 
ALPHA, 2007
7  DCM, LVEF  ≤ 0.40  446 29.5  3.9  1.3 
Cumulative   1500  27.2  5.4 
[4.5 6.4] 
1.7** 
[0.8 2.6] 
 
Number of patients in SCD-HeFT trial excludes amiodarone arm. For abbreviations see 
preceding tables.   24
Figure Legends 
Figure 1.  Cumulative annual event rates (AERs) for MTWA negative and MTWA non-negative 
patients, and associated hazard ratio, in the Low and High ICD Groups.  Bars indicate 95% 
confidence intervals. 
Figure 2.  Clinical algorithm for use of MTWA in evaluating primary prevention patients.   25
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